Lower valuations of Omaxe to be major positives: Emkay
Published on Wed, Jul 18, 2007 at 15:27 , Updated at Wed, Jul 18, 2007 at 15:54
Source : Moneycontrol.com
| ads by google |
Omaxe, a real estate player, is open for subscription with a public issue of 1.78 crore equity shares of Rs 10 each with an additional green shoe option of upto 17.50 lakh equity shares in the band of Rs 265 to Rs 310 per share on July 17. The issue will close for subscription on July 20, 2007. Emkay PCR report on Omaxe IPO Company Overview Omaxe is a real estate development & construction company with projects ranging from integrated townships, group housing and retail & commercial buildings. As of March’07, the company has completed eight residential projects (consisting of seven group housing & one integrated township) and two commercial projects (consisting retail & office space) covering approximately 5.13 million sq.ft of developed area. The company has operations in 30 cities & 9 states in India. As on 31st March07, the company is working on 52 residential & commercial projects (38 under development & 14 under various stages of approvals). As on March 31, 2007 the company has a debt of Rs 12636.5 million of which debt amounting to Rs 4000 million relates to deferred payment for land. Positives
Concerns
Recommendation At the offer price band of Rs 265-310, Omaxe’s PE works out to 17.8 – 20.8 x FY2007 EPS of Rs 14.9 (consolidated) on post issue equity of Rs 1727.5 million. On a relative comparison, Omaxe trades at a lower PE & M.Cap/Sales basis NAV Valuation We value Omaxe using NAV method. We discount the cash flows from the projects in hand on the present land bank at 15% for a period of 5 years. We arrive at a Net Asset Value of Rs 487 per share which is 57% above the upper band of the price range of Rs 265- Rs 310. We feel, company’s strong brand image, focus on Tier2 & Tier 3 cities and lower valuations compared to peers to be major positives. We recommend a subscribe to the issue. |
Messages on IPO, New Issues
Other comments
Chemcel Biotech to list on Oct 13
Chemcel Biotech a company engaged in the business of agro-chemicals will list on the bourses with its equity shares...
in IPO, New Issues - MMB Messenger at 10-Oct-08 12:40
The Govt should motivate the market by slowly and time the nationalisation of some govt undertakings at good price ...
in IPO, New Issues - asana at 10-Oct-08 12:36
Rate this article
News
10-10 Alkali Metals extends its IPO till October 15
10-10 CRISIL reaffirms IPO grade 3/5 to Mandhana Industries IPO
Expert Advice
06-10 20 Microns fully priced at issue price
04-09 Austral Coke's fair value at discount to IPO price
Red Herring Document
| Company | Date |
| KSK Energy Ventures | 14-Feb-2008 |
| Lotus Eye Care Hospital | 01-Feb-2008 |
| Nu Tek India | 16-Jan-2008 |
| Bafna Pharmaceuticals | 27-Dec-2007 |
| Birla Cotsyn (India) | 27-Dec-2007 |
Chat
Ambareesh Baliga
, Karvy Stock Broking
(13 Oct- 16:00hrs)
What's the outlook for the market?
Poll
Newsletter
Keep in touch with News day & night. Subscribe to:
Mobile Services
Get news on the move SMS to 52622
- SMS M for Market News
- SMS B for Latest Business News
- SMS S (stock name) for latest news




Offline



